Form 4: Elevation Oncology Executive Exercises Stock Options, Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
David Dornan, Chief Scientific Officer of Elevation Oncology, exercised stock options and sold shares to cover tax obligations on February 15, 2025.
Summary
- On February 15, 2025, David Dornan, the Chief Scientific Officer of Elevation Oncology, exercised restricted stock units (RSUs) converting into 9,375 shares of common stock.
- Simultaneously, Dornan sold 4,152 shares of common stock at a price of $0.6717 per share to satisfy tax obligations related to the RSU vesting.
- Following these transactions, Dornan directly owns 5,223 shares of Elevation Oncology common stock and 28,125 restricted stock units.
Sentiment
Score: 5
Explanation: The document reflects standard insider trading activity related to compensation and tax obligations, with no indication of positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company executives. It is a standard practice for executives to sell shares to cover tax obligations when stock options or restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/15/2025 | Date of transaction: Exercise of restricted stock units and sale of shares. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.